Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Court Ban On Federal Funding For Embryonic Stem Cell Research Would Help China In Race To Lead The Field

This article was originally published in PharmAsia News

Executive Summary

BEIJING - If a court battle now being waged in the American federal judiciary over embryonic stem cell research ends with a new ban on U.S. government funding for these studies, the freeze would give China a boost in its race to become a dominant power in this field, according to a scholar who tracks stem cell research on both sides of the Pacific

You may also be interested in...



Head Of U.S. National Institutes Of Health Warns Court Ban On Funding For Embryonic Stem Cell Research Could Trigger Flight Of Best Scientists To Rival Centers Abroad

BEIJING - As lawyers for the United States Department of Justice and for those seeking to halt all federal funding for embryonic stem cell research prepare for a new round of battle in a U.S. Court of Appeals, the head of the National Institutes of Health is warning that a funding freeze could trigger an exodus of the best embryonic stem cell scientists to rival centers abroad

China Emerging As World Power In Stem Cell Research

BEIJING - China is speedily evolving into a global power in terms of stem cell research, with the central government stepping up funding and recruiting scientists worldwide in order to catapult the country into the advance ranks of regenerative medicine, according to four scholars at the University of Toronto

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel